HER2 Support Group Forums - View Single Post - for Jean and others trying to figure out the importance of ER+PR- status

Hopeful · 04-22-2008, 09:15 AM

>>ER+/PR- breast cancers defined by RNA profiling were associated with poor patient outcome, worse than those with pure ER+/PR+ patterns; these differences were not observed when using clinical assays to assign ER and PR status.<<

Lani, I understand this to mean that positivity as determined by the standard pathology tests that are run following biopsy differs from that determined by genomic profiling, is that correct? If so, this makes the proposed offering of ER/PR quantitation by Genomic Testing (the Oncotype Dx company) later this year more provocative, as these assays are the basis for much of the fundamental treatment decisions made in clincal practice.

Thanks for posting.

Hopeful

04-22-2008, 09:15 AM	#2
Hopeful Senior Member Join Date: Aug 2006 Posts: 3,380	>>ER+/PR- breast cancers defined by RNA profiling were associated with poor patient outcome, worse than those with pure ER+/PR+ patterns; these differences were not observed when using clinical assays to assign ER and PR status.<< Lani, I understand this to mean that positivity as determined by the standard pathology tests that are run following biopsy differs from that determined by genomic profiling, is that correct? If so, this makes the proposed offering of ER/PR quantitation by Genomic Testing (the Oncotype Dx company) later this year more provocative, as these assays are the basis for much of the fundamental treatment decisions made in clincal practice. Thanks for posting. Hopeful